Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 5/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31737441 | 0.78 | CYP2D6 (0.64) | CYP2D6TSHRCYP1A2CYP3A4MEN1 | |
| SCHEMBL23932472 | 0.78 | CYP2D6 (0.64) | CYP2D6TSHRCYP1A2CYP3A4MEN1 | |
| SCHEMBL13354928 | 0.75 | CYP2D6 (0.52) | CYP2D6TSHRCYP1A2CYP3A4MEN1 | |
| SCHEMBL2420232 | 0.75 | ADRB2 (0.58) | CYP2D6TSHRCYP1A2CYP3A4MEN1 | |
| SCHEMBL31652127 | 0.74 | CYP1A2 (0.52) | CYP2D6TSHRCYP1A2CYP3A4MEN1 | |
| SCHEMBL4344404 | 0.74 | CYP1A2 (0.52) | CYP2D6TSHRCYP1A2CYP3A4MEN1 | |
| SCHEMBL14328423 | 0.74 | CYP2D6 (0.52) | CYP2D6TSHRCYP1A2CYP3A4MEN1 | |
| SCHEMBL23932498 | 0.74 | CYP2D6 (0.52) | CYP2D6TSHRCYP1A2CYP3A4MEN1 | |
| Hydrochloric Acid SCHEMBL2798278 | 0.73 | CYP2D6 (0.51) | CYP2D6TSHRCYP1A2CYP3A4MEN1 | |
| Hydrochloric Acid SCHEMBL2797503 | 0.73 | CYP2D6 (0.51) | CYP2D6TSHRCYP1A2CYP3A4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060199840-A1 | Chemical derivatives and their application as antitelomerase agent | AVENTIS PHARMA S.A. (FR) | 2006-09-07 | — | — | US | disclosed |
| US-6995175-B2 | Chemical derivatives and their application as antitelomerase agent | AVENTIS PHARMA S.A. (FR) | 2006-02-07 | — | — | US | disclosed |
| US-20040138257-A1 | Chemical derivatives and their application as antitelomerase agent | AVENTIS PHARMA S.A. (FR) | 2004-07-15 | — | — | US | disclosed |
| EP-1401833-A2 | CHEMICAL DERIVATIVES AND THE USE THEREOF AS AN ANTI-ELOMERASE AGENT | Aventis Pharma S.A. (FR) | 2004-03-31 | — | — | EP | disclosed |
| WO-2002096903-A2 | CHEMICAL DERIVATIVES AND THE USE THEREOF AS AN ANTI-TELOMERASE AGENT | AVENTIS PHARMA S.A. (FR) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138257-A1 | Chemical derivatives and their application as antitelomerase agent | NTPCR, DPYD, NME1 | CYP2D6 1753/4885TSHR 3754/4885CYP1A2 1551/4885 |
| US-20060199840-A1 | Chemical derivatives and their application as antitelomerase agent | NTPCR, DPYD, NME1 | CYP2D6 1753/4885TSHR 3754/4885CYP1A2 1551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.